WAVERLEY PHARMA INC (WAVE.CA) Stock Price, Forecast & Analysis
TSX-V:WAVE • CA94357L1058
WAVE.CA Key Statistics, Chart & Performance
The current stock price of WAVE.CA is 0.015 CAD. In the past month the price decreased by -25%. In the past year, price decreased by -25%.
WAVE.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to WAVE.CA. When comparing the yearly performance of all stocks, WAVE.CA is a bad performer in the overall market: 92.33% of all stocks are doing better.
WAVE.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA. WAVE.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
WAVE.CA Financial Highlights
Over the last trailing twelve months WAVE.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 83.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
WAVE.CA Forecast & Estimates
WAVE.CA Ownership
WAVE.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 560.189M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 378.8M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 141.303M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 63.392M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 27.297M | ||
| HEM | HEMOSTEMIX INC | N/A | 15.079M | ||
| MPH | MEDICURE INC | N/A | 11.693M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.49M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About WAVE.CA
Company Profile
Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. The company is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. The company also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Company Info
WAVERLEY PHARMA INC
4-1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Larry Thiessen
Employees: 0
Phone: 12049287907
WAVERLEY PHARMA INC / WAVE.CA FAQ
What does WAVERLEY PHARMA INC do?
Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. The company is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. The company also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Can you provide the latest stock price for WAVERLEY PHARMA INC?
The current stock price of WAVE.CA is 0.015 CAD.
What is the dividend status of WAVERLEY PHARMA INC?
WAVE.CA does not pay a dividend.
What is the ChartMill rating of WAVERLEY PHARMA INC stock?
WAVE.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is WAVERLEY PHARMA INC worth?
WAVERLEY PHARMA INC (WAVE.CA) has a market capitalization of 810.00K CAD. This makes WAVE.CA a Nano Cap stock.